Oferta global secundaria propuesta por Pfizer Inc.
NO PARA SU LIBERACIÓN, PUBLICACIÓN O DISTRIBUCIÓN, DIRECTA O INDIRECTA (TOTAL O PARCIALMENTE) EN, HACIA O DESDE CUALQUIER JURISDICCIÓN DONDE HACERLO CONSTITUIRÍA UNA VIOLACIÓN DE LAS LEYES PERTINENTES DE DICHA JURISDICCIÓN
ESTE ANUNCIO CONTIENE INFORMACIÓN INTERIOR
PARA PUBLICACION INMEDIATA
Haleon plc: Proposed Secondary Global Offering by Pfizer Inc. in Haleon plc and Proposed Share Buyback
18 2024 de marzo: Haleon plc ("Haleon") (LSE/NYSE: HLN) announces that Pfizer Inc. ("Pfizer") intends to sell approximately 630 million Haleon ordinary shares ("Ordinary Shares"), including Ordinary Shares in the form of American Depositary Shares, each representing two Ordinary Shares ("ADSs", and together with the Ordinary Shares, the "Securities") by means of a public offering in the United States (the "U.S. Offer"), and a concurrent offering outside the United States to qualifying investors for purposes of, and in accordance with, applicable local laws and regulations in the jurisdictions in which such offer is being made (the "International Offer" and, together with the U.S. Offer, the "Global Offer").
The offering price per Security in the Global Offer will be determined by means of a bookbuilding process and is expected to be announced on or about 19 March 2024, following completion of the bookbuilding.
Pfizer will receive all of the net proceeds from the Global Offer, subject to customary closing conditions. No Securities are being sold or issued by Haleon and Haleon will not receive any of the net proceeds from the Global Offer.
Haleon previously entered into a Share Purchase Deed with Pfizer which was approved by Haleon's shareholders at its Annual General Meeting on 20 April 2023 (the "Share Purchase Deed"), pursuant to which Haleon has the ability to make certain off-market purchases to acquire Ordinary Shares from Pfizer, subject to certain terms and conditions. In connection with the Global Offer and subject to satisfaction of the conditions set out in the Share Purchase Deed, Haleon has agreed to repurchase from Pfizer, and Pfizer has agreed to sell to Haleon, off-market, Ordinary Shares having an aggregate purchase price of approximately £315 million (approximately $400 million) at the same time as, or immediately following and on the same day as, the completion of the Global Offer (the "Share Buyback"). The purchase price per Ordinary Share to be paid by Haleon in the Share Buyback will be equal to the offering price per Ordinary Share in the Global Offer. The Share Buyback is subject to satisfaction of the conditions in the Share Purchase Deed, including the successful completion of the Global Offer and receipt of written confirmation from Haleon's sponsor pursuant to LR11.1.10R(2)(b) of the UK Financial Conduct Authority's Listing Rules that the terms of the Share Buyback are fair and reasonable as far as Haleon's shareholders are concerned.
Completion of the Global Offer and the Share Buyback is expected to reduce Pfizer's interest in Haleon from 32% to approximately 24% of Haleon's issued Ordinary Share capital.
En relación con la Oferta Global, se espera que los Valores de Pfizer estén sujetos a un bloqueo de 90 días a favor de Citigroup y Morgan Stanley, sujeto a las excepciones habituales y a las renuncias. Pfizer ha recibido las exenciones necesarias de los acuerdos de bloqueo existentes para poder participar en la Oferta Global.
Citigroup and Morgan Stanley are serving as Joint Global Coordinators and Joint Bookrunners of the Global Offer. Barclays, J.P. Morgan and UBS Investment Bank are serving as Joint Bookrunners (together with the Joint Global Coordinators, the "Banks") of the Global Offer.
The Global Offer will be made pursuant to a shelf registration statement on Form F-3 filed by Haleon with the United States Securities and Exchange Commission (the "SEC") on 3 July 2023 (the "Registration Statement"), as supplemented by a preliminary prospectus supplement.
Haleon has filed the Registration Statement (including a prospectus) and a preliminary prospectus supplement with the SEG for the Securities to which this communication relates. Before you invest, you should carefully read the prospectus in the Registration Statement, the preliminary prospectus supplement and the documents incorporated by reference in the Registration Statement for more complete information about Haleon and the Global Offer. Haleon intends to file a further prospectus supplement with respect to the Global Offer. You may obtain these documents for free by visiting the SEC website at www.sec.gov. También se pueden obtener copias del suplemento del prospecto preliminar y del prospecto adjunto relacionado con la Oferta Global de Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, por teléfono al 1-800-831-9146, Morgan Stanley en: Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014 A la atención de: Prospectus Department, Barclays en: Barclays Capital Inc., c/o Broadridge Financial Solutions 1155 Long Island Avenue Edgewood, NY 11717, GME@dhr-rgv.com ((888) 603-5847), JP Morgan en: JP Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, Nueva York 11717, teléfono: 1-866-803-9204, o enviando un correo electrónico a GME@dhr-rgv.com y UBS Investment Bank en: UBS Securities LLC, Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019, por teléfono al (888) 827-7275 o por correo electrónico GME@dhr-rgv.com.
Este anuncio no constituirá una oferta de venta o la solicitud de una oferta de compra, ni habrá ninguna venta de Valores en ningún estado u otra jurisdicción en la que, o a cualquier persona a quien, dicha oferta, solicitud o venta le correspondería. ser ilegal antes del registro o calificación según las leyes de valores de dicho estado u otra jurisdicción. La distribución o comunicación de este anuncio o el suplemento del prospecto relacionado con la Oferta Global en ciertas jurisdicciones puede estar restringida por ley. Cualquier oferta podrá ser retirada o revocada, sin obligación o compromiso de ningún tipo, en cualquier momento antes de la notificación de su aceptación dada después de la fecha de entrada en vigor.
Consultas
|
| ||
Inversionistas | Medios
| ||
sonia gobrial | +44 7392 784784 | Zoë Pájaro | +44 7736 746167 |
Rakesh Patel | +44 7552 484646 | nidaa solitaria | +44 7841 400607 |
Emma White | +44 7792 750133
| ||
Email: GME@dhr-rgv.com | Email: GME@dhr-rgv.com |
La persona responsable de organizar la publicación de este anuncio en nombre de Haleon es Amanda Mellor, secretaria de la empresa.
Acerca de Haleon
Haleon (LSE / NYSE: HLN) es un líder mundial en salud del consumidor, con el propósito de brindar una mejor salud todos los días a la humanidad. La cartera de productos de Haleon abarca cinco categorías principales: salud bucal, alivio del dolor, salud respiratoria, salud digestiva y otras, y vitaminas, minerales y suplementos (VMS). Sus marcas de larga data, como Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax y Centrum, se basan en ciencia confiable, innovación y un profundo conocimiento humano.
Para mayor información por favor visite www.haleon.es.
Nota de advertencia sobre las declaraciones prospectivas
Certain statements contained in this announcement are, or may be deemed to be, "forward-looking statements" (including for purposes of the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934). Forward-looking statements give Haleon's current expectations, projections, intentions or beliefs about future events, including strategic initiatives and future financial condition and performance, and so actual results may differ materiality from what is expressed or implied by the statements. These statements sometimes use words such as "expects", "anticipates", "believes", "targets", "plans", "intends", "aims", "projects", "estimates", "indicates", "may", "might", "will", "should", "potential", "could" and other words of similar meaning (or the negative thereof). These forward-looking statements include all matters that are not historical or current facts. In particular, these include, but are not limited to, statements relating to the consummation of the proposed Global Offer by Pfizer, the Share Buyback, and the risks identified, or incorporated by reference, any prospectus supplement or accompanying prospectus.
Cualquier declaración prospectiva realizada por Haleon o en su nombre se refiere únicamente a la fecha en que se realizó y se basa en el conocimiento y la información disponibles para Haleon en la fecha de este anuncio. Estas declaraciones y opiniones pueden basarse en una serie de suposiciones y, por su naturaleza, implican riesgos conocidos y desconocidos, incertidumbres y otros factores porque se relacionan con eventos y dependen de circunstancias que pueden ocurrir o no en el futuro y/o son más allá del control de Haleon o de una estimación precisa. Sujeto a nuestras obligaciones según las leyes inglesas y estadounidenses en relación con la divulgación y la información continua, no asumimos ninguna obligación de actualizar públicamente o revisar ninguna declaración prospectiva, ya sea como resultado de nueva información, eventos futuros o de otro modo.
# # #
En el Reino Unido, este anuncio y su contenido están dirigidos únicamente a (A) "inversores cualificados" en el sentido del artículo 2(e) del Reglamento (UE) 2017/1129 (en su versión modificada), ya que forma parte de la legislación nacional del Reino Unido. en virtud de la Ley (Retirada) de la Unión Europea de 2018; y (B) (i) personas que tengan experiencia profesional en asuntos relacionados con inversiones comprendidas en el artículo 19 de la Orden de 2000 de la Ley de Mercados y Servicios Financieros del Reino Unido de 2005 (Promoción Financiera) (la "Orden"), o (ii) un patrimonio neto elevado entidades y otras personas a quienes pueda comunicarse legalmente de otro modo dentro del Artículo 49(2)(a) a (d) de la Orden, todas esas personas en (A) y (B) se denominan en conjunto "personas relevantes" . Este anuncio no debe ser utilizado ni basado en este anuncio en el Reino Unido por personas que no sean personas relevantes. Cualquier actividad de inversión a la que se refiere este anuncio está disponible en el Reino Unido solo para personas relevantes y se realizará únicamente con personas relevantes.
En el Espacio Económico Europeo (el "EEE"), este anuncio está dirigido únicamente a personas de los Estados miembros que sean "inversores cualificados" en el sentido del artículo 2(e) del Reglamento (UE) 2017/1129. (según enmendado) ("Inversores Calificados"). Este anuncio no debe ser utilizado ni invocado en el EEE por personas que no sean inversores cualificados. Cualquier actividad de inversión a la que se refiere este anuncio está disponible en el EEE solo para inversores calificados y se realizará únicamente con inversores calificados.
The Banks are acting exclusively for Pfizer and no one else in connection with the Global Offer. None of the Banks will regard any other person (whether or not a recipient of this announcement) as a client in relation to the Global Offer and will not be responsible to anyone other than Pfizer for providing the protections afforded to their respective clients nor for giving advice in relation to the Global Offer or any transaction or arrangement referred to in this announcement. No information in this announcement should be construed as providing financial, investment or other professional advice and each prospective investor should consult its own legal, business, tax and other advisers in evaluating any potential investment opportunity.
In connection with the Global Offer, each of the Banks and any of their respective affiliates, acting as investors for their own accounts, may purchase Securities and in that capacity may retain, purchase, sell, offer to sell or otherwise deal for their own accounts in such Securities and other securities of Haleon or related investments in connection with the Global Offer or otherwise. Accordingly, references in the final prospectus supplement to the Securities being offered, subscribed, issued, acquired, sold, placed or otherwise dealt in should be read as including any offer, subscription, issue, sale, acquisition, placing or dealing in the Securities by any of the Banks and any of their affiliates acting as investors for their own accounts. In addition, certain of the Banks or their affiliates may enter into financing arrangements and swaps in connection with which they or their affiliates may from time to time acquire, hold or dispose of Securities. None of the Banks nor any of their respective affiliates intends to disclose the extent of any such investment or transactions otherwise than in accordance with any legal or regulatory obligations to do so.
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.